Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Nephrology

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

The incidence and risk factors of acute kidney injury after hepatobiliary surgery: a prospective observational study

  • Eunjung Cho1,
  • Sun-Chul Kim1,
  • Myung-Gyu Kim1,
  • Sang-Kyung Jo1Email author,
  • Won-Yong Cho1 and
  • Hyoung-Kyu Kim1
BMC Nephrology201415:169

https://doi.org/10.1186/1471-2369-15-169

Received: 22 April 2014

Accepted: 14 October 2014

Published: 23 October 2014

Abstract

Background

Although intraperitoneal surgery is a major operation associated with postoperative acute kidney injury (AKI), the incidence, risk factors, and long-term renal outcome are not well known. We aimed to determine the risk factors and 6 months renal outcome in patients with clinical or subclinical AKI after hepatobiliary surgery. We also assessed the validity of urine neutrophil gelatinase-associated lipocalin (NGAL) in the early detection of AKI or prediction of renal outcome.

Methods

This prospective observational study enrolled patients with normal renal function who underwent hepatobiliary surgeries. Urine and serum samples were collected for NGAL measurement.

Results

Among 131 patients, 10 (7.6%) developed postoperative AKI. Urine NGAL at 12 h postsurgery was the most predictive parameter for the diagnosis of AKI (cutoff, 92.85 ng/mL). With the cutoff value, subclinical AKI was diagnosed in 42 (32.1%) patients. Patients with clinical AKI and those with subclinical AKI were assigned to the AKI group. The AKI group had significantly higher model for end-stage liver disease and sodium (MELD-Na) score, lower albumin level, and longer hospital stay after surgery than the non-AKI group. Older age and higher MELD-Na score were independent risk factors for the development of postoperative AKI. At 6 months postsurgery, the estimated glomerular filtration rate (eGFR) in the AKI group was significantly lower than that in the non-AKI group, although the baseline eGFR was not different. In multiple linear regression analysis, the maximum urine NGAL level during 24 h postsurgery, intraoperative fluid balance, and having liver transplantation were significantly associated with a poor 6 months renal outcome.

Conclusion

Urine NGAL was useful in the early diagnosis of postoperative AKI as well as in predicting the 6 months renal outcome after hepatobiliary surgery. A considerable proportion of patients developed subclinical AKI, and these patients showed worse renal outcome compared with the non-AKI group.

Keywords

Acute kidney injuryPostoperative complicationsNeutrophil gelatinase-associated lipocalin

Background

Intraperitoneal surgery has been known as a common risk factor for postoperative acute kidney injury (AKI) along with cardiac surgery with cardiopulmonary bypass or vascular procedures with aortic cross-clamping. However, the incidence and outcome of AKI after an intraperitoneal procedure is largely unknown because most studies on postoperative AKI have been performed in patients undergoing cardiac surgeries or transplantation. In addition, the validity of new biomarkers in the early detection of AKI or in predicting outcome after intraperitoneal surgery is not known due to the paucity of data.

Since newly emerging biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL) and interleukin-18 have been extensively validated as more sensitive early diagnostic markers for AKI than serum creatinine, the concept of subclinical AKI has recently emerged. Subclinical AKI can be defined as the presence of increased levels of renal tubular injury biomarkers without fulfilling the consensus criteria for AKI based on serum creatinine level or urine output [1]. Although a few studies demonstrated the poor outcome of patients who were classified as having subclinical AKI, the clinical significance of these patients further needs to be determined.

This study first assessed the incidence of postoperative clinical and subclinical AKI in patients with normal baseline renal function who underwent elective hepatobiliary surgeries, one of the most common intraperitoneal surgeries. Then, we compared the characteristics and outcomes between the AKI group (including patients with subclinical AKI) and the non-AKI group, and also determined the diagnostic and prognostic values of urine NGAL in this population.

Methods

Ethics statement

The study protocol was approved by the Institutional Review Board of Korea University Anam Hospital (IRB No. ED11094). Written informed consents were obtained from all patients.

Patients and study design

Patients who planned to undergo elective hepatobiliary surgery in Korea University Anam Hospital were sequentially enrolled from July 2011 to January 2013. Patients <18 years of age, with baseline estimated glomerular filtration rate (eGFR) of <60 ml/min/1.73 m2, on maintenance renal replacement therapy (RRT), or who developed AKI preoperatively were excluded. Blood and urine samples were obtained before surgery (serum NGAL-Pre and urine NGAL-Pre). Urine samples were also obtained postoperatively at 6, 12, and 24 h (urine NGAL-6 h, NGAL-12 h, NGAL-24 h), and serum samples at 24 h (serum NGAL-24 h). Patients were followed up at the outpatient clinic after discharge, and serum creatinine levels were measured at 1, 3, and 6 months after the surgery.

Postoperative clinical AKI was diagnosed according to the Acute Kidney Injury Network (AKIN) criteria (i.e., ≥0.3 mg/dL or a ≥50% increase in the serum creatinine level from the baseline value within 48 h, or a urine output <0.5 mL/kg/hr for ≥6 h). Subclinical AKI was defined as an increase in the serum or urine biomarker (NGAL in this study) level above the determined cutoff value, without meeting the AKIN criteria [24]. This definition was also used in a multicenter pooled analysis by Hasse et al. and patients with subclinical AKI showed poorer outcome compared to non-AKI group who had no increase of both NGAL and serum creatinine [2]. The eGFR was estimated using the Modification of Diet in Renal Disease equation.

We first assessed the diagnostic ability of NGAL for the AKIN criteria-based clinical AKI. Then, we divided the patients into two groups: those with AKI (clinical or subclinical) and those without AKI. Baseline characteristics, surgical characteristics, and outcome variables, including death, length of hospital stay, and decrease of eGFR during the follow-up period, were compared between the two groups.

The primary outcome was the development of postoperative AKI, and the secondary outcomes were the length of hospitalization, postoperative death and the decrease in eGFR at 6 months after the surgery.

Laboratory measurements

Collected blood and urine samples were centrifuged, and the supernatants were stored immediately at -80°C until the biomarker assay. Serum and urine NGAL were measured using NGAL ELISA kit (BioPorto, Gentofte, Denmark) according to the manufacturer’s instructions.

Statistical analysis

SPSS software, version 19.0, was used for statistical analyses. Comparisons between the two groups were performed by the Student’s t-test or the Mann–Whitney U test for numerical data, and χ2 test or Fisher’s exact test for categorical data. To examine the diagnostic performance of urine NGAL for the development of clinical AKI, receiver operating characteristic (ROC) analysis was performed. We conducted multivariate logistic regression analysis to identify the risk factors for the development of clinical or subclinical AKI, and multiple linear regression analysis to identify the predictors for the extent of decrease in eGFR at 6 months postsurgery.

Results

Study population

During the study period, 135 patients, with informed consents, underwent elective hepatobiliary surgeries. Two patients who developed clinical AKI preoperatively and another two patients with a baseline eGFR of <60 ml/min/1.73 m2 were excluded. We enrolled 131 patients (84 male, 63.2%; mean age, 57.0 ± 12.4 years). The patients had the following underlying diseases: hepatocellular carcinoma (41.2%), liver metastasis of other primary cancers (20.6%), cholangiocarcinoma (14.5%), advanced liver cirrhosis for liver transplantation (6.9%), and others including intrahepatic duct stone and biliary cystadenoma. Fifty-five (42.0%) patients underwent hepatectomy alone; 56 (42.7%) underwent hepatectomy along with the resection of another organ, including gall bladder, diaphragm, inferior vena cava, or portal vein; and 20 (15.3%) underwent liver transplantation.

Role of urine NGAL in the early detection of AKI and the incidence of subclinical AKI

Postoperative clinical AKI developed in 10 (7.6%) patients: five in AKIN stage 1, two in stage 2, and three in stage 3. And most (8 of 10) clinical AKI occurred in patients who had liver transplantation. None of the patients with clinical AKI had oliguria or required RRT. Table 1 presents the urine NGAL levels of patients with or without clinical AKI, and shows that the level increased significantly at 12 h postsurgery in patients with AKI compared with that in patients without AKI.The area under the ROC curve of urine NGAL-12 h for predicting clinical AKI was 0.886 (95% CI 0.803-0.969, p <0.001; cutoff 92.85 ng/mL, sensitivity 77.8%, and specificity 80.4%; Figure 1). With the use of this cutoff value and the maximum value of serial urine NGAL levels during 24 h postsurgery, we identified additional 42 (32.1%) patients who developed subclinical AKI and reclassified these patients into the AKI group together with patients who developed clinical AKI. Patients with subclinical AKI accounted for 80.8% (42 of 52) of the AKI group and 80.9% (34 of 42) of patients with subclinical AKI had non-transplant surgery.
Table 1

Serum and urine NGAL levels in patients with or without clinical AKI

NGAL (ng/mL)

Clinical AKI (n =10)

No AKI (n =121)

P

Serum

Pre

161.55 ± 150.69

167.05 ± 130.83

0.900

 

24 h

491.78 ± 517.91

451.70 ± 385.93

0.771

Urine

Pre

39.67 ± 32.60

58.90 ± 156.90

0.700

 

6 h

283.05 ± 350.69

83.51 ± 86.12

0.128

 

12 h

374.20 ± 366.72

72.46 ± 134.34

0.039

 

24 h

257.72 ± 273.39

98.74 ± 145.14

0.121

Figure 1

Receiver operating characteristic (ROC) curves of urine NGAL for the diagnosis of clinical AKI. The areas under the ROC curves are as follows: urine NGAL-6 h, 0.780 (95% CI 0.659-0.901, p = 0.005); urine NGAL-12 h, 0.886 (95% CI 0.803-0.969, p <0.001); urine NGAL-24 h, 0.714 (95% CI 0.549-0.880, p = 0.033).

Comparison of baseline and operation-related characteristics in patients with or without AKI

As shown in Table 2, there were no differences in age, sex, and the prevalence of hypertension, diabetes, or heart disease between the AKI and non-AKI groups. Baseline eGFR was >90 ml/min/1.73 m2 and similar in both groups. However, serum sodium and albumin levels were significantly lower, and total bilirubin level and prothrombin time (international normalized ratio [INR]) were significantly higher in the AKI group than in the non-AKI group. However, the levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were not different between the two groups. As expected, the model for end-stage liver disease and sodium (MELD-Na) score was significantly higher in the AKI group than in the non-AKI group; however, the retention rate of indocyanine green 15 min after administration (ICG-R15), which was examined only in non-transplant patients, showed no difference between the two groups. The proportion of diseases requiring operation showed a significant difference: hepatocellular carcinoma was the most prevalent disease in both groups; liver cirrhosis requiring transplantation was more common in the AKI group; and liver metastasis of other primary cancers was present in >30% of patients in the non-AKI group. Likewise, liver transplantation was performed more frequently and the duration of operation was significantly longer in the AKI group than in the non-AKI group (Table 3). However, blood loss during the operation or the intraoperative and postoperative 24-h fluid balance showed no difference between the two groups, whereas more patients with AKI needed furosemide injection than those without AKI (Table 3). We also analyzed the characteristics of patients with subclinical versus clinical AKI (Additional file 1: Table S1). Patients with subclinical AKI had higher albumin, lower AST level, shorter operation time, and less use of furosemide than patients with clinical AKI. Only 19.0% (8 of 42) patients with subclinical AKI compared to 80.0% (8 of 10) patients with clinical AKI had transplantation.
Table 2

Baseline characteristics

 

AKI group (n =52)

Non-AKI group (n =79)

P

Preoperative (baseline)

Male (%)

35 (67.3)

47 (59.5)

0.461

Age, years

59.06 ± 10.39

55.43 ± 13.47

0.085

Hypertension (%)

18 (34.6)

26 (32.9)

0.852

Diabetes (%)

15 (28.8)

17 (21.5)

0.407

Heart disease (%)1) (EF < 50% or coronary artery disease)

2 (3.8)

2 (2.5)

0.649

Baseline eGFR, ml/min/1.73 m2

94.94 ± 25.41

95.46 ± 20.68

0.898

MELD-Na score

11.46 ± 7.06

8.05 ± 3.11

0.002

Child-Pugh score

6.21 ± 2.18

5.29 ± 1.04

0.006

ICG-R15,%2)

12.79 ± 9.36

12.22 ± 5.96

0.743

Mean arterial pressure, mmHg

86.38 ± 10.19

88.00 ± 9.65

0.359

Total bilirubin, mg/dL

2.27 ± 4.25

0.88 ± 1.80

0.030

Serum Na, mmol/L

138.33 ± 6.01

140.22 ± 2.16

0.034

Prothrombin time, INR

1.23 ± 0.43

1.048 ± 0.23

0.006

Albumin, g/dL

3.70 ± 0.58

3.97 ± 0.55

0.009

ALT, IU/L

25.85 ± 15.10

28.47 ± 40.10

0.653

AST, IU/L

35.15 ± 16.22

30.28 ± 25.18

0.218

CRP, mg/L

6.56 ± 16.40

10.33 ± 35.99

0.503

Reason for operation (%)

<0.001

Hepatocellular carcinoma

29 (55.8)

25 (31.6)

 

Liver metastasis

3 (5.8)

24 (30.4)

 

Cholangiocarcinoma

9 (17.3)

10 (12.7)

 

Liver cirrhosis

7 (13.5)

2 (2.5)

 

Others

4 (7.7)

18 (22.8)

 

1)Ejection fraction <50% or coronary artery disease, 2)Measured only in patients with no liver transplantation.

Table 3

Operation-related characteristics

 

AKI group (n =52)

Non-AKI group (n =79)

P

Duration, min

483.27 ± 274.72

366.20 ± 187.84

0.009

Fluid balance, mL

2425 ± 3024

1696 ± 2342

0.145

Blood loss, mL

431 ± 1070

303 ± 487

0.353

Postoperative 24-h fluid balance, mL

872 ± 1523

1135 ± 1521

0.335

Use of furosemide (%)

16 (30.8)

9 (11.4)

0.011

Types of operation (%)

<0.001

Hepatectomy

15 (28.8)

40 (50.6)

 

Hepatectomy + other operation

21 (40.4)

35 (44.3)

 

Liver transplantation

16 (30.8)

4 (5.1)

 

Risk factors for the development of AKI

Next, we performed multivariate logistic regression analysis to determine the preoperative risk factors for the development of clinical and subclinical AKI. The preoperative variables included were as follows: age, sex, hypertension, diabetes mellitus, preoperative albumin and ALT levels, and MELD-Na score. We identified that older age and higher MELD-Na score were independent predictors for the development of postoperative AKI (Table 4).
Table 4

Preoperative risk factors for the development of AKI

 

Odds ratio

95% CI

P

Age

1.040

1.005 – 1.076

0.024

MELD-Na score

1.184

1.071 – 1.308

0.001

Postoperative changes of eGFR and outcome measures

One hundred and ten (84.0%) patients completed 6-month follow-up visits and laboratory tests. Table 5 presents the changes in eGFR from baseline to 6 months postsurgery and the other outcome measures. Whereas eGFR levels at 1 and 3 months postsurgery were not different, eGFR in the AKI group at 6 months postsurgery was significantly lower than that in the non-AKI group (p =0.007). The postoperative hospital stay was also significantly longer in the AKI group. However, there was no difference in mortality between the two groups during the 6-month follow-up period.
Table 5

Changes of eGFR during 6 months of follow-up and outcomes

 

AKI group

Non-AKI group

P

eGFR

Baseline

94.94 ± 25.41

95.46 ± 20.68

0.898

At discharge

95.03 ± 36.34

105.69 ± 24.99

0.049

1 month

89.74 ± 28.38

95.79 ± 19.40

0.158

3 months

86.46 ± 26.32

89.87 ± 18.82

0.413

6 months

79.61 ± 18.22

88.97 ± 16.88

0.007

Hospital stay after surgery, days

22.4 ± 22.9

13.0 ± 10.1

0.007

Death during 6 months

3 (5.8%)

2 (2.5%)

0.385

Significant differences in the 6-month eGFR and hospital stay were still noted when only patients with subclinical AKI and those without AKI were compared (eGFR at 6 months, 80.62 ± 16.07 versus 88.97 ± 16.88 ml/min/1.73 m2, p =0.020; hospital stay, 17.2 ± 11.6 versus 13.0 ± 10.1 days, p =0.047). However, there was no difference in mortality between the two groups (Table 6).
Table 6

Comparison of outcomes in the non-AKI, subclinical AKI, and clinical AKI groups

 

Non-AKI (n =79)

Subclinical AKI (n =42)

Clinical AKI (n =10)

Baseline eGFR

95.46 ± 20.68

90.96 ± 21.86

98.34 ± 12.35

eGFR at 6 months

88.97 ± 16.88

80.62 ± 16.07*

76.24 ± 24.81*

Hospital stay after surgery

13.0 ± 10.1

17.2 ± 11.6*

44.1 ± 41.4*

Death during 6 months

2 (2.5%)

3 (7.1%)

0 (0%)

*P <0.05 compared with the non-AKI group. Outcomes were not significantly different between patients with subclinical AKI and those with clinical AKI.

Predictors of 6 months renal outcome

We evaluated the parameters independently associated with the degree of changes in eGFR at 6 months postsurgery (ΔeGFR = eGFR at 6 months – baseline eGFR) by multiple linear regression analysis. The maximum level of urine NGAL (p =0.011), a positive intraoperative fluid balance (p =0.027), and having liver transplantation (p =0.012) were significantly and negatively associated with ΔeGFR after adjustment for age, sex, hypertension, diabetes, MELD-Na score, and length of operation (Table 7).
Table 7

Multiple linear regression analysis of the degree of changes in eGFR 6 months post surgery

 

B

Standard error

Beta

P

95% CI

Constant

-6.288

9.963

 

0.529

-26.054 to 13.478

Age

0.042

0.145

0.026

0.771

-0.245 to 0.329

Sex

2.591

3.196

0.065

0.420

-3.750 to 8.931

Hypertension

4.104

3.635

0.098

0.262

-3.108 to 11.315

Diabetes

-0.649

3.871

-0.014

0.867

-8.329 to 7.031

MELD-Na score

0.150

0.390

0.043

0.702

-0.624 to 0.924

Fluid balance during operation

-0.002

0.001

-0.219

0.027

-0.003 to 0.000

Length of operation

-0.003

0.010

-0.035

0.768

-0.022 to 0.016

Urine NGAL, max.

-0.016

0.006

-0.221

0.011

-0.028 to -0.004

Liver transplantation

-18.830

7.315

-0.358

0.012

-33.343 to -4.318

F =6.888, R2 = 0.383, P <0.001.

Discussion

AKI is an important postoperative complication that increases morbidity and mortality, with an incidence ranging from 10% to 30% after a major surgery [5, 6]. In a retrospective study of 10,518 patients with normal renal function, postoperative AKI was associated with increased mortality even in patients who recovered their renal function at the time of hospital discharge [5]. In another study, patients with postoperative AKI were reported to have more dependency in the activities of daily living at 6 months after discharge [6].

In contrast to cardiac or vascular surgery, the incidence or risk factors of AKI after intraperitoneal surgery are not well known due to the paucity of data. In our study population of patients with a baseline eGFR of ≥60 ml/min/1.73 m2 who underwent elective hepatobiliary surgery, 7.6% developed AKIN criteria-based clinical AKI but none needed RRT. The overall incidence and severity of AKI were much lower than those in a previous report that demonstrated an incidence of AKI of 15.1% after hepatic resection [7]. Although direct comparison of the patients’ baseline and operative characteristics is difficult, the higher prevalence of chronic kidney disease (CKD) (12.8%) in the previous study might be one reason for this discrepancy.

We next tested the validity of serum and urine NGAL in the early detection of AKI. NGAL is the most widely studied biomarker for AKI; however, most studies have been performed in patients undergoing cardiac surgery or transplantation [813]. As expected, we found that urine NGAL obtained at 12 h postsurgery was the most predictive parameter for the detection of AKI, with a cutoff value of 92.85 ng/mL. Serum NGAL did not show predictive value in our population partly because it can rise in liver injury. Organs other than kidney, such as liver, lung, and gastrointestinal tract, also express NGAL under physiologic condition and the expression is increased under injured or post-operative condition [14]. Our previous study with critically ill patients and another study with liver transplant patients also presented the usefulness of urinary NGAL compared to plasma NGAL in the prediction of AKI or prognosis [15, 16]. Although another study performed in patients undergoing cardiac surgery presented a similar value (87 ng/mL) [11], the optimal cutoff values for detecting postoperative AKI vary across studies. In addition, defining the proper time point for sample collection is also important. Several previous studies performed in patients undergoing cardiac surgery or liver transplantation suggest that NGAL levels at 0–6 h postsurgery are meaningful for the early detection of AKI [811, 13, 17], whereas a study performed in patients undergoing non-cardiac major surgery showed no correlation of NGAL levels at 2 or 6 h postsurgery with the development of AKI [18]. In our study, we also observed that urine NGAL-12 h, but not NGAL-6 h, reliably predicts clinical AKI in patients undergoing hepatobiliary surgeries. Concerning the proper cutoff value or time point, further larger studies with different types of surgeries are needed.

Recent advances in biomarker research have made it possible to identify patients who showed only increased levels of tubular injury markers without fulfilling the consensus criteria for AKI. Those patients could not have been recognized in the pre-biomarker era because their urine output and serum creatinine levels are well maintained. However, several recent studies demonstrated that patients with this type of subclinical AKI comprises 15-20% of patients admitted to an intensive care unit or an emergency department, and they have increased risk of death or need for dialysis compared with patients without elevated levels of tubular damage markers [2, 19]. In our study, with an NGAL cutoff value of 92.85 ng/mL, >30% of patients who underwent elective hepatobiliary surgery developed subclinical AKI. We then included these patients in the AKI group (n =52, 39.7%) and compared their preoperative risk factors with those of the non-AKI group.

Among several factors that were significantly different between the AKI and non-AKI groups in univariate analysis, older age and higher MELD-Na score were found to be independent preoperative risk factors for AKI after hepatobiliary surgery. Although several models for predicting AKI after cardiac surgery, such as Continuous Improvement in Cardiac Surgery Study and Cleveland Clinic Score, have been proposed and validated extensively [20], only few studies developed a prediction model for AKI in non-cardiac surgeries [7, 21]. Kheterpal et al., by reviewing 152,244 operations, identified 11 independent preoperative predictors of AKI after general surgeries: age ≥56 years, male sex, emergency surgery, intraperitoneal surgery, diabetes mellitus necessitating oral or insulin therapy, active congestive heart failure, ascites, hypertension, and mild to moderate preoperative renal insufficiency [21]. More recently, Slankamenac et al. developed and validated an AKI prediction score system in patients undergoing liver resection, similar with our study. In that study, they noted that postoperative AKI developed in 15.1% and that preoperatively elevated ALT level, preexisting cardiovascular disease, chronic renal failure, and diabetes were the strongest predictors of AKI defined by the RIFLE criteria [7]. Although our study did not aim to develop a prediction model for postoperative AKI and had a small sample size for validating a new model, we could identify that old age and high MELD-Na score were significant risk factors for postoperative AKI after hepatobiliary surgery. On the other hand, ALT or the presence of diabetes was not associated with the development of postoperative AKI in our study. The major differences between our study and Slankamenac et al.’s were that we excluded patients with CKD or those who underwent emergency surgeries and included patients with subclinical AKI. These results could suggest that in patients without CKD, age and the degree of underlying liver dysfunction might be more important in the development of postoperative AKI.

It is noteworthy that preoperative MELD-Na score that includes the INR of prothrombin time, and bilirubin, serum creatinine, and Na levels can be considered risk factors for postoperative AKI even in patients with normal renal function. No study to date has investigated the predictive role of the scoring system in postoperative complications. The MELD incorporating serum sodium, known as “MELD-Na”, was developed for the outcome prediction of cirrhosis and is considered to have better prognostic ability than the Child-Pugh classification or the MELD [22, 23]. In addition, the MELD-Na score has also been reported to be significantly related to survival in patients with hepatocellular carcinoma or pancreatic and gastric cancer-related ascites [2426]. Similarly, we also observed that a high preoperative MELD-Na score was independently associated with the development of AKI after hepatobiliary surgery. We chose the MELD-Na score instead of the MELD score because we observed that the Na level was significantly lower in the AKI group in univariate analysis, in addition to the significantly prolonged prothrombin time (INR), elevated serum bilirubin level, and lower albumin level.

Interestingly, we assigned patients with subclinical AKI to the AKI group and compared the outcomes. While dialysis requiring AKI is a well-known factor of poor outcome of AKI such as longer hospital stay, higher mortality, and predisposition to end-stage renal disease, we observed in our study that patients with stage 1, 2, or 3 without the need for RRT or even those with subclinical AKI had significantly longer hospital stay and worse 6 months eGFR than the non-AKI group. The difference was also confirmed by a separate analysis between patients with subclinical AKI and the non-AKI group patients. To the best of our knowledge, this is the first study that demonstrated that even subclinical postoperative AKI might portend poor long-term renal outcome. Although our patients with subclinical AKI still had an eGFR of 80 ml/min/1.73 m2 after 6 months of observation, further studies with a longer follow-up period would show a larger impact on patients’ renal outcome. Moreover, the maximum level of urine NGAL, which was used for the diagnosis of subclinical AKI, was demonstrated to be independently associated with the extent of loss of renal function at 6 months postsurgery, even after the adjustment for other variables including liver transplantation.

All these findings in our study could strengthen the important role of urine NGAL as a sensitive biomarker and an outcome predictor of postoperative AKI, and also emphasize the need for recognizing and evaluating patients who develop subclinical AKI.

Along with urine NGAL, having liver transplantation was also demonstrated to be independently associated with poor long-term postoperative renal outcome. In addition to the possibility that frequent development of AKI after liver transplantation leads to worse renal outcome, another possibility for worse 6 month renal outcome in liver transplantation might include the unavoidable use of immunosuppressive drugs such as calcineurin inhibitors. Another factor that was independently associated with worse 6 months renal outcome was a positive fluid balance during the operation. Previous reports also highlighted the importance of fluid overload as a risk factor for death and lack of renal recovery in patients with AKI; therefore, restricted perioperative fluid administration was recommended to reduce postoperative complications and mortality [2733]. Our study, by demonstrating worse long-term renal outcome, reaffirms the negative impact of positive fluid balance in hepatobiliary surgeries. This association was still significant even after the adjustment for liver transplantation, age, or MELD-Na score.

Despite several novel findings, this study has some limitations. It is a single-center prospective study, and its small sample size restricted the development or validation of a model for predicting postoperative AKI or long-term renal outcome. In addition, we only enrolled patients with normal renal function and only four patients had heart diseases, which may limit the general application of the results of this study. We excluded patients with eGFR <60 ml/min/1.73 m2 because decreased eGFR can be a confounding factor in interpreting the incidence of post-operative AKI and the 6 months renal outcome post surgery. Inclusion of patients irrespective of the type of hepatobiliary surgery, including liver transplantation, might also be a limitation. However, we adjusted for liver transplantation when analyzing the risk factors for 6 months renal outcome. Furthermore, as already mentioned, more frequent follow-up examinations of serum or urine NGAL levels may show additional information, although urine NGAL-12 h was the most predictive parameter for determining AKI in our patients. Finally, we observed the patients for only 6 months. Although our study identified several important findings, these results need to be further validated in a larger cohort of patients with a longer follow-up period.

Conclusions

In conclusion, 7.6% and 32.1% of patients with normal baseline renal function undergoing elective hepatobiliary surgery developed clinical and subclinical AKI, respectively. Older age and higher MELD-Na score were risk factors for postoperative AKI. Urine NGAL was demonstrated to be useful both for the early diagnosis of postoperative AKI and for the prediction of 6 months renal outcome. In addition, liver transplantation and positive intraoperative fluid balance as well as urine NGAL were associated with poor 6 months renal outcome. Further studies of postoperative AKI in patients undergoing different types of surgeries or with different morbidities are needed to validate the role of biomarkers and find predictors of outcomes.

Declarations

Authors’ Affiliations

(1)
Division of Nephrology, Department of Internal Medicine, Korea University Anam Hospital

References

  1. Haase M, Kellum JA, Ronco C: Subclinical AKI–an emerging syndrome with important consequences. Nat Rev Nephrol. 2012, 8: 735-739. 10.1038/nrneph.2012.197.View ArticlePubMedGoogle Scholar
  2. Haase M, Devarajan P, Haase-Fielitz A, Bellomo R, Cruz DN, Wagener G, Krawczeski CD, Koyner JL, Murray P, Zappitelli M, Goldstein SL, Makris K, Ronco C, Martensson J, Martling CR, Venge P, Siew E, Ware LB, Ikizler TA, Mertens PR: The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J Am Coll Cardiol. 2011, 57: 1752-1761. 10.1016/j.jacc.2010.11.051.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Bagshaw SM: Subclinical acute kidney injury: a novel biomarker-defined syndrome. Crit Care Resusc. 2011, 13: 201-203.PubMedGoogle Scholar
  4. Ronco C, Kellum JA, Haase M: Subclinical AKI is still AKI. Crit Care. 2012, 16: 313-10.1186/cc10920.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Bihorac A, Yavas S, Subbiah S, Hobson CE, Schold JD, Gabrielli A, Layon AJ, Segal MS: Long-term risk of mortality and acute kidney injury during hospitalization after major surgery. Ann Surg. 2009, 249: 851-858. 10.1097/SLA.0b013e3181a40a0b.View ArticlePubMedGoogle Scholar
  6. Abelha FJ, Botelho M, Fernandes V, Barros H: Outcome and quality of life of patients with acute kidney injury after major surgery. Nefrologia. 2009, 29: 404-414.PubMedGoogle Scholar
  7. Slankamenac K, Breitenstein S, Held U, Beck-Schimmer B, Puhan MA, Clavien PA: Development and validation of a prediction score for postoperative acute renal failure following liver resection. Ann Surg. 2009, 250: 720-728. 10.1097/SLA.0b013e3181bdd840.View ArticlePubMedGoogle Scholar
  8. Che M, Xie B, Xue S, Dai H, Qian J, Ni Z, Axelsson J, Yan Y: Clinical usefulness of novel biomarkers for the detection of acute kidney injury following elective cardiac surgery. Nephron Clin Pract. 2010, 115: c66-c72. 10.1159/000286352.View ArticlePubMedGoogle Scholar
  9. Li Y, Zhu M, Xia Q, Wang S, Qian J, Lu R, Che M, Dai H, Wu Q, Ni Z, Lindholm B, Axelsson J, Yan Y: Urinary neutrophil gelatinase-associated lipocalin and L-type fatty acid binding protein as diagnostic markers of early acute kidney injury after liver transplantation. Biomarkers. 2012, 17: 336-342. 10.3109/1354750X.2012.672458.View ArticlePubMedGoogle Scholar
  10. Liu S, Che M, Xue S, Xie B, Zhu M, Lu R, Zhang W, Qian J, Yan Y: Urinary L-FABP and its combination with urinary NGAL in early diagnosis of acute kidney injury after cardiac surgery in adult patients. Biomarkers. 2013, 18: 95-101. 10.3109/1354750X.2012.740687.View ArticlePubMedGoogle Scholar
  11. Munir MU, Khan DA, Khan FA, Shahab Naqvi SM: Rapid detection of acute kidney injury by urinary neutrophil gelatinase-associated lipocalin after cardiopulmonary bypass surgery. J Coll Physicians Surg Pak. 2013, 23: 103-106.PubMedGoogle Scholar
  12. Niemann CU, Walia A, Waldman J, Davio M, Roberts JP, Hirose R, Feiner J: Acute kidney injury during liver transplantation as determined by neutrophil gelatinase-associated lipocalin. Liver Transpl. 2009, 15: 1852-1860. 10.1002/lt.21938.View ArticlePubMedGoogle Scholar
  13. Sargentini V, Mariani P, DA M, Pistolesi V, Lauretta MP, Pacini F, Tritapepe L, Morabito S, Bachetoni A: Assessment of NGAL as an early biomarker of acute kidney injury in adult cardiac surgery patients. J Biol Regul Homeost Agents. 2012, 26: 485-493.PubMedGoogle Scholar
  14. Shemin D, Dworkin LD: Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for early acute kidney injury. Crit Care Clin. 2011, 27: 379-389. 10.1016/j.ccc.2010.12.003.View ArticlePubMedGoogle Scholar
  15. Yang HN, Boo CS, Kim MG, Jo SK, Cho WY, Kim HK: Urine neutrophil gelatinase-associated lipocalin: an independent predictor of adverse outcomes in acute kidney injury. Am J Nephrol. 2010, 31: 501-509. 10.1159/000309841.View ArticlePubMedGoogle Scholar
  16. Jeong TD, Kim S, Lee W, Song GW, Kim YK, Chun S, Lee SG, Min WK: Neutrophil gelatinase-associated lipocalin as an early biomarker of acute kidney injury in liver transplantation. Clin Transplant. 2012, 26: 775-781. 10.1111/j.1399-0012.2012.01610.x.View ArticlePubMedGoogle Scholar
  17. Buelow MW, Dall A, Regner K, Weinberg C, Bartz PJ, Sowinski J, Rudd N, Katzmark L, Tweddell JS, Earing MG: Urinary interleukin-18 and urinary neutrophil gelatinase-associated lipocalin predict acute kidney injury following pulmonary valve replacement prior to serum creatinine. Congenit Heart Dis. 2012, 7: 441-447. 10.1111/j.1747-0803.2012.00662.x.View ArticlePubMedGoogle Scholar
  18. Shavit L, Dolgoker I, Ivgi H, Assous M, Slotki I: Neutrophil gelatinase-associated lipocalin as a predictor of complications and mortality in patients undergoing non-cardiac major surgery. Kidney Blood Press Res. 2011, 34: 116-124. 10.1159/000323897.View ArticlePubMedGoogle Scholar
  19. Nickolas TL, Schmidt-Ott KM, Canetta P, Forster C, Singer E, Sise M, Elger A, Maarouf O, Sola-Del Valle DA, O’Rourke M, Sherman E, Lee P, Geara A, Imus P, Guddati A, Polland A, Rahman W, Elitok S, Malik N, Giglio J, El-Sayegh S, Devarajan P, Hebbar S, Saggi SJ, Hahn B, Kettritz R, Luft FC, Barasch J: Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: a multicenter prospective cohort study. J Am Coll Cardiol. 2012, 59: 246-255. 10.1016/j.jacc.2011.10.854.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Huen SC, Parikh CR: Predicting acute kidney injury after cardiac surgery: a systematic review. Ann Thorac Surg. 2012, 93: 337-347.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Kheterpal S, Tremper KK, Heung M, Rosenberg AL, Englesbe M, Shanks AM, Campbell DA: Development and validation of an acute kidney injury risk index for patients undergoing general surgery: results from a national data set. Anesthesiology. 2009, 110: 505-515. 10.1097/ALN.0b013e3181979440.View ArticlePubMedGoogle Scholar
  22. Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, Benson J, Therneau T, Kremers W, Wiesner R, Kamath P, Klintmalm G: Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology. 2006, 130: 1652-1660. 10.1053/j.gastro.2006.02.010.View ArticlePubMedGoogle Scholar
  23. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM, Wolfe RA, Krom R: Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003, 124: 91-96. 10.1053/gast.2003.50016.View ArticlePubMedGoogle Scholar
  24. Engin H, Bilir C, Ustundag Y: MELD-sodium score and its prognostic value in malignancy-related ascites of pancreatic and gastric cancer. Support Care Cancer. 2013, 21: 1153-1156. 10.1007/s00520-012-1640-3.View ArticlePubMedGoogle Scholar
  25. Huo TI, Lin HC, Hsia CY, Huang YH, Wu JC, Chiang JH, Chiou YY, Lui WY, Lee PC, Lee SD: The MELD-Na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: a prospective survey. Dig Liver Dis. 2008, 40: 882-889. 10.1016/j.dld.2008.01.015.View ArticlePubMedGoogle Scholar
  26. Lee YH, Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Loong CC, Chiou YY, Huo TI: Defining the severity of liver dysfunction in patients with hepatocellular carcinoma by the model for end-stage liver disease-derived systems. Dig Liver Dis. 2012, 44: 868-874. 10.1016/j.dld.2012.04.018.View ArticlePubMedGoogle Scholar
  27. Bouchard J, Soroko SB, Chertow GM, Himmelfarb J, Ikizler TA, Paganini EP, Mehta RL: Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int. 2009, 76: 422-427. 10.1038/ki.2009.159.View ArticlePubMedGoogle Scholar
  28. Brandstrup B, Tonnesen H, Beier-Holgersen R, Hjortso E, Ording H, Lindorff-Larsen K, Rasmussen MS, Lanng C, Wallin L, Iversen LH, Gramkow CS, Okholm M, Blemmer T, Svendsen PE, Rottensten HH, Thage B, Riis J, Jeppesen IS, Teilum D, Christensen AM, Graungaard B, Pott F: Effects of intravenous fluid restriction on postoperative complications: comparison of two perioperative fluid regimens: a randomized assessor-blinded multicenter trial. Ann Surg. 2003, 238: 641-648. 10.1097/01.sla.0000094387.50865.23.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Eng OS, Goswami J, Moore D, Chen C, Gannon CJ, August DA, Carpizo DR: Intraoperative fluid administration is associated with perioperative outcomes in pancreaticoduodenectomy: A single center retrospective analysis. J Surg Oncol. 2013, 108: 242-247. 10.1002/jso.23393.View ArticlePubMedGoogle Scholar
  30. Heung M, Wolfgram DF, Kommareddi M, Hu Y, Song PX, Ojo AO: Fluid overload at initiation of renal replacement therapy is associated with lack of renal recovery in patients with acute kidney injury. Nephrol Dial Transplant. 2012, 27: 956-961. 10.1093/ndt/gfr470.View ArticlePubMedGoogle Scholar
  31. Lobo DN, Bostock KA, Neal KR, Perkins AC, Rowlands BJ, Allison SP: Effect of salt and water balance on recovery of gastrointestinal function after elective colonic resection: a randomised controlled trial. Lancet. 2002, 359: 1812-1818. 10.1016/S0140-6736(02)08711-1.View ArticlePubMedGoogle Scholar
  32. Payen D, de Pont AC, Sakr Y, Spies C, Reinhart K, Vincent JL: A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care. 2008, 12: R74-10.1186/cc6916.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Tambyraja AL, Sengupta F, MacGregor AB, Bartolo DC, Fearon KC: Patterns and clinical outcomes associated with routine intravenous sodium and fluid administration after colorectal resection. World J Surg. 2004, 28: 1046-1051. 10.1007/s00268-004-7383-7. discussion 1051–1052View ArticlePubMedGoogle Scholar
  34. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2369/15/169/prepub

Copyright

© Cho et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement